PHGN.F Pharming Group NV

Healthcare Biotechnology Frankfurt Exchange
1.17 EUR
Close of Nov 13, 2026
0.8194 1.76
Market cap
EUR 830M
P/E
39.1x
P/B
3.14x
ROE
8.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PHGN.F undervalued?

Graham number
Price1.17
Graham value0.5025
Premium133.5%

PHGN.F trades 133.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharming Group NV fundamental analysis

No fundamental analysis for Pharming Group NV yet.

Pharming Group NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treat…

Full company profile